Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na<sup>+</sup>/H<sup>+</sup> Exchanger Isoform 3-Reference-Cited by-同舟云学术

Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na⁺/H⁺ Exchanger Isoform 3

Published:2022-04-11 Issue:7 Volume:13 Page:1043-1051
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Jacobs Jeffrey W.¹,Leadbetter Michael R.¹,Bell Noah¹,Koo-McCoy Samantha¹,Carreras Christopher W.¹,He Limin¹,Kohler Jill¹,Kozuka Kenji¹,Labonté Eric D.¹,Navre Marc¹,Spencer Andrew G.¹,Charmot Dominique¹

Affiliation:

1. Ardelyx, Inc., 400 Fifth Avenue, Suite 210, Waltham, Massachusetts 02451, United States

Funder

Ardelyx, Inc.

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.2c00037

Reference29 articles.

1. Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis

2. New treatment targets for the management of irritable bowel syndrome

3. Update on Pharmacotherapy for Irritable Bowel Syndrome

4. NHE3 regulatory complexes

5. Regulatory Binding Partners and Complexes of NHE3

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023);Journal of Medicinal Chemistry;2024-07-12

2. Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney Failure;Journal of Renal Nutrition;2024-07

3. NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons;American Journal of Physiology-Gastrointestinal and Liver Physiology;2024-05-01

4. Synthesis and Monoamine Oxidase Inhibition Properties of 4-(2-Methyloxazol-4-yl)benzenesulfonamide;Molbank;2024-03-06

5. Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study;Kidney360;2024-02-07